Posts By :

Michael

Lysogene Reports its Cash Position as of 31 March 2021
Lysogene Reports its Cash Position as of 31 March 2021 150 150 Lysogene

Cash and cash equivalents of €20.0 million* as of 31 March 2021 Paris, France —…

Lysogene Announces Filing of 2020 Universal Registration Document
Lysogene Announces Filing of 2020 Universal Registration Document 150 150 Lysogene

Paris, France — 13 April 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…

Lysogene Reports Full Year 2020 Financial Results and Provides Operational Update
Lysogene Reports Full Year 2020 Financial Results and Provides Operational Update 150 150 Lysogene

Positive biomarker data reported with LYS-SAF302 for the treatment of MPS IIIANew program entering the…

Lysogene Reports its Cash Position as of 31 December 2020
Lysogene Reports its Cash Position as of 31 December 2020 150 150 Lysogene

Cash and cash equivalents of €18.8 million* as of 31 December 2020 Paris, France —…

Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021
Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021 150 150 Lysogene

Evidence of positive biological response to LYS-SAF302 in patients treated in the AAVance clinical trial~30%…

Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis
Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

Second country to authorize trial initiation after recent UK MHRA approval, further country approvals pendingTrial…

Lysogene Secures €5 million in Non-Dilutive Financing
Lysogene Secures €5 million in Non-Dilutive Financing 150 150 Lysogene

Approval received from BRED for a €5 million non-dilutive financing in the form of PGE…

Lysogene announces its financial calendar for 2021
Lysogene announces its financial calendar for 2021 150 150 Lysogene

Paris, France — 25 January 2021 at 08:00am — Lysogene (FR0013233475 – LYS), a phase…

Lysogene Reports Positive Biomarker data with LYS-SAF302
Lysogene Reports Positive Biomarker data with LYS-SAF302 150 150 Lysogene

Decrease in heparan sulfate concentration in cerebrospinal fluidDecrease in GM2 and GM3 ganglioside in cerebrospinal…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top